We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Chad Therapeutics, | AMEX:CTU | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
RNS Number:1722K Conister Trust PLC 17 April 2003 Conister Trust PLC Scrip Dividend The Board of Conister Trust PLC announces that it will be offering a scrip dividend alternative in lieu of the final cash dividend of 0.6p per share which was recently announced as being proposed in respect of the Company's year ended 31 December 2002. The reference price of 32p per share is based on the average of the middle market quotations for the Company's shares for the five business days commencing 9 April 2003 as derived from the Daily Official List. The entitlement is therefore 1 new ordinary share for every 54 ordinary shares held on the dividend record date of 11 April 2003. In accordance with the Company's Articles of Association any balance remaining will be carried forward to the next dividend payment date. If all shareholders opt to receive ordinary shares in lieu of their dividends, a maximum of 456,210 shares would be issued representing 1.85 per cent of the current issued share capital. Application will be made for up to 456,210 ordinary shares to be admitted to AIM in respect of the scrip dividend alternative on 23 May 2003. A scrip dividend alternative letter is being sent to all shareholders on 17 April 2003 and copies are available from the Company Secretary, Conister Trust PLC, PO Box 17, Douglas, Isle of Man, IM99 1AR. This information is provided by RNS The company news service from the London Stock Exchange END MSCNKOKKNBKDFQD
1 Year Chad Therapeutics Chart |
1 Month Chad Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions